🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASCO25 update on CheckMate 77T: Periop nivo vs plb in resectable NSCLC (mFUP 41 mo) M.Provencio 🔹 EFS: 46.6 vs 16.9 mo (HR 0.61), 30-mo 61% vs 43% 🔹 Benefit regardless of KRAS, STK11, KEAP1, PD-L1 status 🔹 ctDNA/pCR linked to EFS 🔹 OS NR trend HR 0.85 (30mo 78% vs 72%)

🫁 Resectable #NSCLC—an area where we have seen a lot of scientific developments! 💥 Big updates coming at #ASCO25 today! 👇 Here’s a refresher on where we stand today! 🔍 Let’s see how the treatment landscape may evolve 🌄, looking forward to a great session today!

Could when you get chemo-immunotherapy affect how long you live?! ▫️1st RCT: Infusions before 3PM = better PFS & OS in advanced NSCLC ▫️Benefit regardless of PD-L1 ▫️Early timing = stronger CD8+ T cell response But are outcomes tied to access? Could subQ ICI help? #ASCO25 ASCO

Results from #DeLLphi304 Phase 3 trial in NEJM #Tarlatamab vs Chemotherapy as 2L for advanced #SmallCell #LungCancer 🫁 ✅ mOS: 13.6 vs 8.3 months (HR 0.60) ✅ Grade ≥3 AEs: 54% vs 80% ✅ #CRS & #ICANS mostly grade 1/2 ‼️ This is practice changing and practice confirming

So excited for this session and so proud to see Rafeh Naqash, MD deservedly on the podium leading this session!! Kudos! ASCO #ASCO25

👏 Incredible presentation & major congrats to Patrick Forde + team! A 10% absolute 5-yr OS improvement is remarkable—esp. when chemo alone gave us just ~5%! This truly shifts the #NSCLC paradigm 🧠 With both neoadjuvant & perioperative trials showing OS benefit… ◼️ What’s the

Dr. Jamie Chaft presents #NeoADAURA💥 Neoadjuvant osimertinib ± chemo in resectable EGFR+ NSCLC ◼️ MPR: 26% (Osi+CT) vs 25% (Osi) vs 2% (CT) ◼️ N2 → N1/0 nodal downstaging ◼️ EFS: Immature but trends in favor of Osi Still unclear if adjuvant osimertinib alone (without chemo)

#ASCO25 Insightful discussion by Lizza Hendriks on perioperative strategies focusing on: ✔️subgroups of patients in need for escalation: nonPCR, PDL1neg, non-ctDNA clearance, p53(+) for EGFR ✔️ways to improve pCR rates: CRT, ICI combos, ADCs? Ami for EGFR+ #some #LCSM ASCO

Amazing discussion Lizza Hendriks putting these studies in great global context! Kudos!

📣Hot off the press: IMforte presented by Dr. Luis Paz-Ares at #ASCO25 Addition of lurbinectedin to atezolizumab in maintenance for 1L ES-SCLC improves: ⭐️PFS (HR 0.54, 5.4 vs 2.1m) ⭐️mOS from maint randomization (HR 0.73, 13.2 vs 10.6m) ⚠️ Heme tox (FN 1.7%) ➡️New SOC for 1L

Congrats to the 2025 FASCO Recipients! ⁦ASCO⁩ #ASCO2025 ⁦Aakash Desai, MD, MPH, FASCO⁩ ⁦UAB Medicine⁩ ⁦UAB O'Neal Comprehensive Cancer Center⁩

Top #LungCancer Oncologists from ASCO 2025. Follow us for more #ASCO25 updates: t.ly/7TCD6 #LARVOL #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | Aakash Desai, MD, MPH, FASCO | Stephen V Liu, MD | Hidehito HORINOUCHI | Diego A. Díaz García | David Heredia. |

Reactions on top trials during ASCO 2025 curated by LARVOL CLIN. Follow us for more #ASCO25 updates: t.ly/7TCD6 #LARVOL #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsights #ASCO2025 | Aakash Desai, MD, MPH, FASCO | Dr Amol Akhade | Aya Mohamed | MSc, MD 🎗 | Diego A. Díaz García |

The Top Most Active Cancer Institutes that were leading the conversation during the ASCO 2025, ranked based on oncologists' reactions and engagement on X. Follow us for more #ASCO25 updates: t.ly/7TCD6 #LARVOL #CancerResearch #Oncology #CancerData

Something's coming... 🫁 +🎙️#staytuned Follow @oncnewscentral and @lunccancerrx for the exciting launch this week! Eric K. Singhi, MD @fawziaburous @adesaimd Jill Feldman EGFR Resisters #lungcancer #NSCLC #SCLC #ASCO25

LAUNCHING on Friday 6/13!! 🎙️ Stay tuned!!

🎙️ Excited to launch our new LungCancerRx 🫁💊 podcast in partnership with Oncology News Central this Friday, 6/13! We kick off with a powerful first episode featuring Jill Feldman from EGFR Resisters. Tune in on #AppleMusic and #Spotify. Don’t miss it! #LungCancer #Oncology #LCSM

Can't wait for this new LungCancerRx 🫁💊 podcast with Jill Feldman of the EGFR Resisters! Congratulations to Aakash Desai, MD, MPH, FASCO Fawzi Abu Rous, MD and Eric K. Singhi, MD for this new collaboration! #LCSM